Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution

Upsala Journal of Medical Sciences

Volumn 117, Issue 1, 2012, Pages 28-34

  MacHaczka, MacIej ^a   Hast, Robert ^b   Dahlman, Ingrid ^a   Lerner, Richard ^a   Klimkowska, Monika ^a   Engvall, Martin ^a   Hgglund, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse events; Gaucher disease; Miglustat; Substrate reduction therapy

Indexed keywords

1 DEOXYNOJIRIMYCIN; DRUG DERIVATIVE; ENZYME INHIBITOR; MIGLUSTAT;

ADULT; AGED; ARTICLE; FEMALE; GAUCHER DISEASE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FEMALE; GAUCHER DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84857227936     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2011.641609     Document Type: Article

References (22)

1. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29: 567-83. (Pubitemid 351614580)
2. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372:1263-71.
3. Mehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med. 2006;17:S2-5. (Pubitemid 44441904)
4. Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: First German long-term results. Skeletal Radiol. 2001;30: 496-503. (Pubitemid 32894331)
5. Rudzki Z, Okon K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease-A histological study. Eur J Haematol. 2003; 70:273-81. (Pubitemid 36560524)
6. de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis. Blood. 2006;108:830-5. (Pubitemid 44154614)
7. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash- Cheng A, Zimran A, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119-26. (Pubitemid 46032604)
8. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481-5. (Pubitemid 30237353)
9. Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: The ZAGAL project. Haematologica. 2009; 94:1771-5.
10. Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Forcemajeure: Therapeuticmeasures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44:41-7.
11. Machaczka M, Lerner R, Klimkowska M, HägglundH. Treatment of multiple myeloma in patients with Gaucher disease. Am J Hematol. 2009;84:694-6.
12. Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: A pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29:1645-54. (Pubitemid 47494543)
13. Mikosch P, Reed M, Baker R, Holloway B, Berger L, Mehta AB, et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int. 2008;83: 43-54.
14. Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-Authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770-7.
15. Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, et al. Dietary modifications in patients receiving miglustat. J Inherit Metab Dis. 2010 Sep 16 (Epub ahead of print).
16. Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34:991-1001.
17. Lachmann RH, te VruchteD, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis. 2004;16:654-8. (Pubitemid 38942998)
18. Bembi B, Marchetti F, Guerci VI, Ciana G, Addobbati R, Grasso D, et al. Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology. 2006;66:278-80. (Pubitemid 43970176)
19. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37:298-314. (Pubitemid 46439676)
20. Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745-52.
21. Chérin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, et al. The neurological manifestations of Gaucher disease type 1: The French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33: 331-8.
22. Biegstraaten M, Mengel E, Maródi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: A 2-year prospective observational study. Brain. 2010;133:2909-19.